"We know that dealing with disorders of the brain is very difficult, and we sympathize with the plaintiff in this case and his family," the statement said. "During the trial, the jury heard evidence that the FDA-approved label properly warned of Risperdal's potential side effects, that the plaintiff's physical condition was not caused by using the medication, and that the plaintiff benefited from using Risperdal."